Dr Lee T Wimberly, MD | |
50 Medical Park Dr E, Birmingham, AL 35235-3401 | |
(205) 838-3000 | |
(205) 874-8333 |
Full Name | Dr Lee T Wimberly |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Experience | 27 Years |
Location | 50 Medical Park Dr E, Birmingham, Alabama |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033142054 | NPI | - | NPPES |
51004675 | Other | AL | BCBS OF ALABAMA |
P00343661 | Other | MEDICARE RAILROAD | |
51530447 | Other | AL | BLUE CROSS BLUE SHIELD |
009933124 | Medicaid | AL | |
051557907 | Medicaid | AL |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | 23248 (Alabama) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Optum Palliative And Hospice Care, Inc | Birmingham, AL | Hospice |
St. Vincent's East | Birmingham, AL | Hospital |
Birmingham Nursing And Rehabilitation Center East | Birmingham, AL | Nursing home |
Trussville Health & Rehabilitation Center | Trussville, AL | Nursing home |
East Glen | Birmingham, AL | Nursing home |
Fair Haven | Birmingham, AL | Nursing home |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Russellville Hospital Inc. | 3476878489 | 83 |
Dermaccel Llc | 7618323130 | 2 |
Eastern Hospital Medicine Pc | 8325044597 | 25 |
News Archive
Big news this afternoon on the Affordable Care Act: The ACA exchange signups have reached the 6 million mark. With a few more days to go before the open sign-up period closes (well, sort of) it looks like the original 7 million estimate - which the Congressional Budget Office had revised downward after the botched October roll-out of the federal exchange - is going to be pretty close to the mark.
A long-time clinician and researcher on Marfan syndrome who helped identify the syndrome's genetic cause and a potential treatment will be honored by the March of Dimes.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
The U.S. Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
› Verified 3 days ago
Entity Name | Eastern Hospital Medicine Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1104859123 PECOS PAC ID: 8325044597 Enrollment ID: O20061011000241 |
News Archive
Big news this afternoon on the Affordable Care Act: The ACA exchange signups have reached the 6 million mark. With a few more days to go before the open sign-up period closes (well, sort of) it looks like the original 7 million estimate - which the Congressional Budget Office had revised downward after the botched October roll-out of the federal exchange - is going to be pretty close to the mark.
A long-time clinician and researcher on Marfan syndrome who helped identify the syndrome's genetic cause and a potential treatment will be honored by the March of Dimes.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
The U.S. Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
› Verified 3 days ago
Entity Name | Russellville Hospital Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1780232314 PECOS PAC ID: 3476878489 Enrollment ID: O20191018002761 |
News Archive
Big news this afternoon on the Affordable Care Act: The ACA exchange signups have reached the 6 million mark. With a few more days to go before the open sign-up period closes (well, sort of) it looks like the original 7 million estimate - which the Congressional Budget Office had revised downward after the botched October roll-out of the federal exchange - is going to be pretty close to the mark.
A long-time clinician and researcher on Marfan syndrome who helped identify the syndrome's genetic cause and a potential treatment will be honored by the March of Dimes.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
The U.S. Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
› Verified 3 days ago
Entity Name | Dermaccel Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1992582241 PECOS PAC ID: 7618323130 Enrollment ID: O20231019001715 |
News Archive
Big news this afternoon on the Affordable Care Act: The ACA exchange signups have reached the 6 million mark. With a few more days to go before the open sign-up period closes (well, sort of) it looks like the original 7 million estimate - which the Congressional Budget Office had revised downward after the botched October roll-out of the federal exchange - is going to be pretty close to the mark.
A long-time clinician and researcher on Marfan syndrome who helped identify the syndrome's genetic cause and a potential treatment will be honored by the March of Dimes.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
The U.S. Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Lee T Wimberly, MD Po Box 830674, Msc#716, Birmingham, AL 35283-0674 Ph: (205) 874-8300 | Dr Lee T Wimberly, MD 50 Medical Park Dr E, Birmingham, AL 35235-3401 Ph: (205) 838-3000 |
News Archive
Big news this afternoon on the Affordable Care Act: The ACA exchange signups have reached the 6 million mark. With a few more days to go before the open sign-up period closes (well, sort of) it looks like the original 7 million estimate - which the Congressional Budget Office had revised downward after the botched October roll-out of the federal exchange - is going to be pretty close to the mark.
A long-time clinician and researcher on Marfan syndrome who helped identify the syndrome's genetic cause and a potential treatment will be honored by the March of Dimes.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
The U.S. Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
› Verified 3 days ago
Juan Mario Bernal, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3680 Grandview Pkwy Ste 200, Birmingham, AL 35243 Phone: 205-971-7500 | |
Dr. William Randolph Maddox, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 Princeton Ave Sw, Birmingham, AL 35211 Phone: 205-783-3000 Fax: 205-297-9411 | |
Jodie Ann Dionne, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 703 19th St S Bldg 206, Birmingham, AL 35233 Phone: 205-975-6530 | |
Dr. Karl Tullio Schroeder, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 817 Princeton Ave Sw Ste 199, Birmingham, AL 35211 Phone: 205-780-1920 Fax: 205-780-2345 | |
Dr. Deepti Bahl, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 6th Ave S, Birmingham, AL 35233 Phone: 205-934-9999 | |
Amitkumar Mehta, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1720 2nd Ave S # Np2540t, Birmingham, AL 35294 Phone: 205-996-8400 Fax: 205-934-1608 | |
Shana Monika Machado, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-4011 |